Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30091954 | 1.00 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL17823774 | 1.00 | P2RX3 (1.00) | P2RX3P2RX2 | |
| Hydrochloric Acid SCHEMBL30092200 | 0.99 | P2RX3 (0.98) | P2RX3P2RX2 | |
| Hydrochloric Acid SCHEMBL21875531 | 0.99 | P2RX3 (0.98) | P2RX3P2RX2 | |
| Hydrochloric Acid SCHEMBL17824135 | 0.99 | P2RX3 (0.98) | P2RX3P2RX2 | |
| SCHEMBL17824240 | 0.95 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL19950204 | 0.95 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL29441128 | 0.95 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL23387534 | 0.92 | P2RX3 (0.88) | P2RX3P2RX2 | |
| SCHEMBL17823670 | 0.92 | P2RX3 (0.88) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110256418-B | 1, 3-thiazol-2-yl substituted benzamides | 拜耳公司 | 2023-01-20 | — | — | CN | disclosed |
| EP-3587417-B9 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2022-03-30 | — | — | EP | disclosed |
| EP-3587417-B1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2022-01-05 | — | — | EP | disclosed |
| EP-3230281-B1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2021-05-26 | — | — | EP | disclosed |
| EP-3793553-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | Bayer Aktiengesellschaft (DE) | 2021-03-24 | — | — | EP | disclosed |
| EP-3793554-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | Bayer Aktiengesellschaft (DE) | 2021-03-24 | — | — | EP | disclosed |
| US-10183937-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183937-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | P2RX3 578/4885P2RX2 541/4885 |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | P2RX3 578/4885P2RX2 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.